|
|
|
Volumn 2, Issue 10, 2001, Pages 1395-1400
|
|
Oprelvekin: Genetics Institute
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
I KAPPA B;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
INTERLEUKIN 11;
INTERLEUKIN 12;
INTERLEUKIN 16;
INTERLEUKIN 1BETA;
NITRIC OXIDE;
PLATELET DERIVED GROWTH FACTOR;
RECOMBINANT INTERLEUKIN 11;
TUMOR NECROSIS FACTOR ALPHA;
BONE MARROW DEPRESSION;
CANCER;
CHEMOTHERAPY;
CLINICAL TRIAL;
COLITIS;
CONJUNCTIVITIS;
CROHN DISEASE;
DISEASE PREDISPOSITION;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG FORMULATION;
DRUG INDICATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
DYSPNEA;
EDEMA;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOSTIMULATION;
LICENSING;
MAJOR CLINICAL STUDY;
MUCOSA INFLAMMATION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PSORIASIS;
REGULATORY MECHANISM;
REVIEW;
RHEUMATOID ARTHRITIS;
STRUCTURE ACTIVITY RELATION;
TACHYCARDIA;
THROMBOCYTE TRANSFUSION;
THROMBOCYTOPENIA;
ANIMALS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
INFLAMMATORY BOWEL DISEASES;
INTERLEUKIN-11;
RECOMBINANT PROTEINS;
STRUCTURE-ACTIVITY RELATIONSHIP;
THROMBOCYTOPENIA;
|
|
EID: 0034771376
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (12)
|
|
References (38)
|
